Detection and quantification of mutations in the plasma of patients with colorectal tumors
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The early detection of cancers through analysis of circulating DNA could have a substantial impact on morbidity and mortality. To achieve this goal, it is essential to determine the number of mutant molecules present in the circulation of cancer patients and to develop methods that are sufficiently sensitive to detect these mutations. Using a modified version of a recently developed assay for this purpose, we found that patients with advanced colorectal cancers consistently contained mutant adenomatous polyposis coli ( APC ) DNA molecules in their plasma. The median number of APC DNA fragments in such patients was 47,800 per ml of plasma, of which 8% were mutant. Mutant APC molecules were also detected in >60% of patients with early, presumably curable colorectal cancers, at levels ranging from 0.01% to 1.7% of the total APC molecules. These results have implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a crucial consideration when considering cfDNA as a template as its concentration can range considerably; from 2 to 30 ng/ml plasma in healthy individuals to 180–600 ng/ml plasma both during pregnancy and in cancer patients (13,16,18,22–24).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Self-citationJahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D., & Knippers, R. (2001) · PubMed · Cited by 2,549
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
(1977) · PubMed · Cited by 1,801
Rapid Clearance of Fetal DNA from Maternal Plasma
Lo, Y. M. D., Zhang, J., Leung, T. N., Lau, T. K., Chang, A. M. Z., & Hjelm, N. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302205 · Cited by 1,157
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples
Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., et al. (1991) · Science · doi:10.1126/science.2024123 · Cited by 875
Self-citationDressman, D., Yan, H., Traverso, G., Kinzler, K. W., & Vogelstein, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133470100 · Cited by 844
Self-citation
Research works printed but not linked: 4
- 10.1002/(SICI)1096-9896(200001)190:1<6::AID-PATH486>3.0.CO;2-M · doi:10.1002/(sici)1096-9896(200001)190:1<6::aid-path486>3.0.co;2-m
- Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. (1977) Cancer Res. 37, 646-650.837366
- Sozzi, G., Conte, D., Mariani, L., Lo Vullo, S., Roz, L., Lombardo, C., Pierotti, M. A. & Tavecchio, L. (2001) Cancer Res. 61, 4675-4678.11406535
- Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D. & Knippers, R. (2001) Cancer Res. 61, 1659-1665.11245480
Cited by
Items 401–500 of 1,000
DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
Ruth E Board, Knight, L., Greystoke, A., Blackhall, F. H., Hughes, A. M., Dive, C., & Ranson, M. (2007) · Biomarker Insights · doi:10.1177/117727190700200003 · Cited by 84
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1700902 · Cited by 63
Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 54
Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients
Rincón-Torroella, J., Khela, H. S., Bettegowda, A., & Bettegowda, C. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03837-0 · Cited by 53
Free circulating DNA as possible tumour marker in colorectal cancer
Boni, L., Cassinotti, E., Canziani, M., Dionigi, G., Rovera, F. A., & Dionigi, R. (2007) · Surgical Oncology · doi:10.1016/j.suronc.2007.10.004 · Cited by 55
A liquid biopsy for head and neck cancers
Schmidt, H., Kulasinghe, A., Perry, C., Nelson, C. C., & Punyadeera, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1127758 · Cited by 52
Dietz, S., Schirmer, U. B., Mercé, C., von Bubnoff, N. C. C., Dahl, E., Meister, M. A., Muley, T., Thomas, M., & Sültmann, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161012 · Cited by 57
Patient monitoring through liquid biopsies using circulating tumor DNA
Ulz, P., Heitzer, E., Geigl, J. B., & Speicher, M. R. (2017) · International Journal of Cancer · doi:10.1002/ijc.30759 · Cited by 56
Genetic profiling of cancer with circulating tumor DNA analysis
Lu, L., Bi, J., & Bao, L. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.11.006 · Cited by 56
Cinti, S., Cinotti, G., Parolo, C., Nguyen, E. P., Caratelli, V., Moscone, D., Arduini, F., & Merkoçi, A. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02560 · Cited by 51
Noninvasive Screening Tests for Colorectal Cancer
Imperiale, T. F. (2012) · Digestive Diseases · doi:10.1159/000341884 · Cited by 57
Chevillet, J. R., Khokhlova, T. D., Giraldez, M. D., Schade, G. R., Starr, F., Wang, Y.-N., Gallichotte, E. N., Wang, K., Hwang, J. H., & Tewari, M. (2016) · Radiology · doi:10.1148/radiol.2016160024 · Cited by 54
Kumar, M., Srivastava, S. C., Singh, S. A., Das, A. K., Das, G. C., Dhar, B., Ghosh, S. K., & Mondal, R. (2017) · Tumor Biology · doi:10.1177/1010428317736643 · Cited by 53
Liquid Biopsy in Tumor Genetic Diagnosis
Jung, A., & Kirchner, T. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0169 · Cited by 55
Spindler, K. G., Pallisgaard, N., Appelt, A. L., Andersen, R. F., Schou, J. V., Nielsen, D. L., Pfeiffer, P., Yilmaz, M., Johansen, J. S., Høgdall, E. V. S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.118 · Cited by 56
Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer
Takai, E., & Yachida, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i38.8480 · Cited by 58
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers
Venesio, T., Siravegna, G., Bardelli, A., & Sapino, A. (2017) · Pathobiology · doi:10.1159/000473882 · Cited by 55
Liquid biopsy and its role in an advanced clinical trial for lung cancer
Johann, D. J., Steliga, M. A., Shin, I. J., Yoon, D., Arnaoutakis, K., Hutchins, L. F., Liu, M., Liem, J., Walker, K., Pereira, A., et al. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370217750087 · Cited by 56
Neutrophil Extracellular Traps: A Walk on the Wild Side of Exercise Immunology
Beiter, T., Fragasso, A., Hartl, D., & Niess, A. M. (2014) · Sports Medicine · doi:10.1007/s40279-014-0296-1 · Cited by 54
Circulating tumour markers can define patients with normal colons, benign polyps and cancers
Mead, R. J., Bhandari, P., Duku, M., & Cree, I. A. (2011) · Gut · doi:10.1136/gut.2011.239301.4 · Cited by 49
Sato, K. A., Hachiya, T., Iwaya, T., Kume, K., Matsuo, T., Kawasaki, K., Abiko, Y., Akasaka, R., Matsumoto, T., Otsuka, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146275 · Cited by 59
Denis, J. A., Guillerm, E., Coulet, F., Larsen, A. K., & Lacorte, J. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0287-7 · Cited by 53
Liebs, S., Keilholz, U., Kehler, I., Schweiger, C., Haybäck, J., & Nonnenmacher, A. (2019) · Cancer Medicine · doi:10.1002/cam4.2219 · Cited by 51
Martuszewski, A., Paluszkiewicz, P., Król-Kulikowska, M., Banasik, M., & Kepinská, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020193 · Cited by 56
The Role of Cell-Free DNA in Cancer Treatment Decision Making
Telekes, A., & Horváth, A. (2022) · Cancers · doi:10.3390/cancers14246115 · Cited by 58
Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection
Perrone, F., Lampis, A., Bertan, C. M., Verderio, P., Ciniselli, C. M., Pizzamiglio, S., Frattini, M., Nucifora, M., Molinari, F., Gallino, G., et al. (2014) · Tumori Journal · doi:10.1177/030089161410000201 · Cited by 48
ASBL, O. B. O. I. P., Keppens, C., Dequeker, E. M. C., Patton, S. J., Normanno, N., Fenizia, F., Butler, R., Cheetham, M. H., Fairley, J. A., Williams, H. L., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4694-x · Cited by 52
Facile profiling of molecular heterogeneity by microfluidic digital melt
O’Keefe, C. M., Pisanic, T. R., Zec, H. C., Overman, M. J., Herman, J. G., & Wang, T. (2018) · Science Advances · doi:10.1126/sciadv.aat6459 · Cited by 49
Papadopoulos, N. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_9 · Cited by 54
Size distribution of cell-free DNA in oncology
Udomruk, S., Orrapin, S., Pruksakorn, D., & Chaiyawat, P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103455 · Cited by 60
Kern, S. E., Shi, C., & Hruban, R. H. (2010) · The Journal of Pathology · doi:10.1002/path.2813 · Cited by 49
Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis
Tóth, K., Barták, B. K., Tulassay, Z., & Molnar, B. A. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1132164 · Cited by 51
Liquid biopsy: unlocking the potentials of cell-free DNA
Chu, D. T. W., & Park, B. H. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2137-8 · Cited by 54
Zhao, Y., He, J., Zou, Y., Guo, X., Cui, J., Guo, L., & Bu, H. (2019) · BMC Neurology · doi:10.1186/s12883-019-1554-5 · Cited by 46
Underhill, H. R. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00534-6 · Cited by 55
Brooks, J. D., Cairns, P., Shore, R. E., Klein, C. B., Wirgin, I. I., Afanasyeva, Y., & Zeleniuch‐Jacquotte, A. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.05.006 · Cited by 47
Screening for circulating RAS/RAF mutations by multiplex digital PCR
Andersen, R. F., & Jakobsen, A. K. M. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.007 · Cited by 51
Mayo‐de‐las‐Casas, C., Garzón‐Ibáñez, M., Jordana‐Ariza, N., García‐Peláez, B., Balada‐Bel, A., Villatoro, S., Malapelle, U., Karachaliou, N., Troncone, G., Rosell, R., et al. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1407243 · Cited by 50
Clinical Perspective and Translational Oncology of Liquid Biopsy
Fernández‐Lázaro, D., García, J. L., Caballero-García, A., del Castillo, A. C., Hueso, M. V., & Cruz, J. J. (2020) · Diagnostics · doi:10.3390/diagnostics10070443 · Cited by 53
Liquid biopsies for residual disease and recurrence
Wan, J. C. M., Mughal, T. I., Razavi, P., Dawson, S., Moss, E. L., Govindan, R., Tan, I. B., Yap, Y. S., Robinson, W. A., Morris, C. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.001 · Cited by 50
Marinello, A., Tagliamento, M., Pagliaro, A., Conci, N., Cella, E., Vasseur, D., Remón, J., Lévy, A., Dall’Olio, F. G., & Besse, B. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102791 · Cited by 53
Margolin, G., Petrykowska, H. M., Jameel, N., Bell, D. W., Young, A., & Elnitski, L. L. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.004 · Cited by 51
Vivancos, A. P., Aranda, E., Benavides, M., Élez, E., Gómez‐España, M. A., Toledano‐Fonseca, M., Álvarez, M., Chica-Parrado, M. D. R., García‐Barberán, V., & Díaz‐Rubio, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-45616-y · Cited by 50
Li, F., Fang, W., Huang, W.-L., Lin, C., Li, L., Shen, M., Yan, Q., Liao, W., Chia, D., Tu, M. K., et al. (2020) · Cancers · doi:10.3390/cancers12082041 · Cited by 50
Chibuk, J., Flory, A., Kruglyak, K. M., Leibman, N. F., Nahama, A., Dharajiya, N. G., van den Boom, D., Jensen, T. J., Friedman, J. S., Shen, M. R., et al. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.664718 · Cited by 52
Self-citationTumor circulating DNA profiling in xenografted mice exposed to intermittent hypoxia
Cortese, R., Almendros, I., Wang, Y., & Gozal, D. (2014) · Oncotarget · doi:10.18632/oncotarget.2785 · Cited by 47
Zanetti‐Dällenbach, R., Wight, E., Fan, A. X., Lapaire, O., Hahn, S., Holzgreve, W., & Zhong, X. Y. (2008) · PubMed · Cited by 45
Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis
Saha, S., Araf, Y., & Promon, S. K. (2022) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-022-00109-4 · Cited by 52
Lewis, J. M., Heineck, D. P., & Heller, M. J. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1069709 · Cited by 52
Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?
Bresalier, R. S., Kopetz, S., & Brenner, D. E. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3575-2 · Cited by 44
BEAMing Up Personalized Medicine: Mutation Detection in Blood
Richardson, A. L., & Iglehart, J. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0871 · Cited by 47
Vrba, L., Oshiro, M. M., Kim, S. S., Garland, L. L., Placencia, C., Mahadevan, D., Nelson, M. A., & Futscher, B. W. (2019) · Epigenetics · doi:10.1080/15592294.2019.1695333 · Cited by 47
Buedts, L., Włodarska, I., Finalet-Ferreiro, J., Gheysens, O. S., Dehaspe, L., Tousseyn, T., Fornecker, L., Lazarovici, J., Casasnovas, O., Gac, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003039 · Cited by 45
Circulating Biomarkers of Colorectal Cancer (CRC)—Their Utility in Diagnosis and Prognosis
Łukaszewicz‐Zając, M., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112391 · Cited by 47
Overview of DNA Sequencing Strategies
Shendure, J., Porreca, G. J., & Church, G. M. (2008) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb0701s81 · Cited by 54
Zmetakova, I., Danihel, Ľ., Smolková, B., Mego, M., Kajabová, V. H., Krivulcik, T., Rusnak, I., Rychlý, B., Daniš, D., Repiská, V., et al. (2013) · Neoplasma · doi:10.4149/neo_2013_082 · Cited by 46
Hickmann, A., Frick, M., Hadaschik, D., Battke, F., Bittl, M., Ganslandt, O., Biskup, S., & Döcker, D. (2019) · BMC Cancer · doi:10.1186/s12885-019-5394-x · Cited by 45
Inns, J., & James, V. H. (2015) · The Breast · doi:10.1016/j.breast.2015.04.001 · Cited by 43
New blood markers detection technology: A leap in the diagnosis of gastric cancer
Beeharry, M. K., Liu, W.-T., Yan, M., & Zhu, Z.-G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1202 · Cited by 42
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
Zhou, Q. X., Perakis, S. O., Ulz, P., Mohan, S., Riedl, J. M., Talakić, E., Lax, S., Tötsch, M., Höefler, G., Bauernhofer, T., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-0719-6 · Cited by 47
Andersson, D., Kristiansson, H., Kubista, M., & Ståhlberg, A. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1889371 · Cited by 43
Kuhlmann, J. D., Schwarzenbach, H., Wimberger, P., Poetsch, M., Kimmig, R., & Kasimir‐Bauer, S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-325 · Cited by 44
Müller, I., Beeger, C., Alix‐Panabières, C., Rébillard, X., Pantel, K., & Schwarzenbach, H. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.099333 · Cited by 45
Hamam, D., Abdouh, M., Gao, Z., Arena, V., Arena, M., & Arena, G. O. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0360-9 · Cited by 43
Zhou, J., Chang, L., Guan, Y., Yang, L., Xia, X., Cui, L., Yi, X., & Lin, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159708 · Cited by 45
The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
Bønløkke, S., Stougaard, M., Sørensen, B. S., Booth, B. B., Høgdall, E. V. S., Nyvang, G., Lindegaard, J. C., Blaakær, J., Bertelsen, J., Fuglsang, K., et al. (2022) · Cells · doi:10.3390/cells11142170 · Cited by 105
Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma
Huet, S., & Salles, G. A. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00691 · Cited by 42
Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review
Thusgaard, C. F., Korsholm, M., Koldby, K. M., Kruse, T. A., Thomassen, M., & Jochumsen, K. M. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.020 · Cited by 43
Hallermayr, A., Wohlfrom, T., Steinke‐Lange, V., Benet‐Pagès, A., Scharf, F., Heitzer, E., Mansmann, U., Haberl, C., de Wit, M., Vogelsang, H., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01342-z · Cited by 42
Cerebrospinal fluid: A unique source of circulating tumor DNA with broad clinical applications
Hickman, R. A., Miller, A. M., & Arcila, M. E. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101688 · Cited by 44
Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma
Huang, X., Duijf, P. H. G., Sriram, S., Perera, G. S., Vasani, S. S., Kenny, L., Leo, P., & Punyadeera, C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00953-z · Cited by 42
Mikrotröpfchen in Mikrofluidiksystemen: eine Technik für Entdeckungen in der Chemie und Biologie
Theberge, A. B., Courtois, F., Schaerli, Y., Fischlechner, M., Abell, C., Hollfelder, F., & Huck, W. T. S. (2010) · Angewandte Chemie · doi:10.1002/ange.200906653 · Cited by 41
Aung, K. L., Board, R. E., Ellison, G., Donald, E., Ward, T., Clack, G., Ranson, M., Hughes, A., Newman, W., & Dive, C. (2010) · The HUGO Journal · doi:10.1007/s11568-011-9149-2 · Cited by 40
Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer Therapy
Oellerich, M., Schütz, E., Beck, J., & Walson, P. D. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000566 · Cited by 41
Peng, M., Xie, Y., Li, X., Qian, Y., Tu, X., Yao, X., Cheng, F., Xu, F., Kong, D., He, B., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105825 · Cited by 40
Li, B., Pu, K., Ge, L., & Wu, X. (2019) · Gene · doi:10.1016/j.gene.2019.143993 · Cited by 41
North, P. E., Ziegler, E., Mahnke, D. K., Stamm, K., Thomm, A. M., Daft, P. G., Goetsch, M. A., Liang, H., Baker, M. A., Vepraskas, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227385 · Cited by 44
Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons
Andersen, R. F., Spindler, K. G., Brandslund, I., Jakobsen, A. K. M., & Pallisgaard, N. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.011 · Cited by 42
Electrochemical analysis of nucleic acids as potential cancer biomarkers
Bartošík, M., & Moráňová, L. (2019) · Current Opinion in Electrochemistry · doi:10.1016/j.coelec.2019.01.002 · Cited by 40
Liquid biopsies in pancreatic cancer
Kamyabi, N., Bernard, V., & Maitra, A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1670063 · Cited by 45
Direct plasmonic detection of circulating RAS mutated DNA in colorectal cancer patients
D’Agata, R., Bellassai, N., Allegretti, M., Rozzi, A., Korom, S., Manicardi, A., Melucci, E., Pescarmona, E. O., Corradini, R., Giacomini, P., et al. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112648 · Cited by 42
Melotte, V., Yi, J. M., Lentjes, M. H. F. M., Smits, K. M., Neste, L. V., Niessen, H. E. C., Wouters, K. A. D., Louwagie, J., Schuebel, K. E., Herman, J. G., et al. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0198 · Cited by 40
Cell Free DNA of Tumor Origin Induces a ‘Metastatic’ Expression Profile in HT-29 Cancer Cell Line
Fűri, I., Kalmár, A., Wichmann, B., Spisák, S., Schöller, A., Barták, B. K., Tulassay, Z., & Molnar, B. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131699 · Cited by 43
Levels of Circulating Cell-Free Serum DNA in Benign and Malignant Breast Lesions
Zanetti-Dällenbach, R. A., Schmid, S., Wight, E., Holzgreve, W., Ladewig, A., Hahn, S., & Zhong, X. Y. (2007) · The International Journal of Biological Markers · doi:10.1177/172460080702200202 · Cited by 38
New applications of CRISPR/Cas9 system on mutant DNA detection
Jia, C., Huai, C., Ding, J., Hu, L., Su, B., Chen, H., & Lu, D. (2017) · Gene · doi:10.1016/j.gene.2017.10.023 · Cited by 39
Lee, H., Na, W., Park, C., Park, K. H., & Shin, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23766-9 · Cited by 42
Technical considerations for circulating tumor DNA detection in oncology
Franczak, C., Filhine-Trésarrieu, P., Gilson, P., Merlin, J., Au, L., & Harlé, A. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1568873 · Cited by 40
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
Filipska, M., & Rosell, R. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12983 · Cited by 42
Tracking tumor resistance using 'liquid biopsies'
Pantel, K., Diaz, L. A., & Polyák, K. (2013) · Nature Medicine · doi:10.1038/nm.3233 · Cited by 38
Self-citationMicrosatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer
Schwarzenbach, H., Chun, F. K. ‐., Müller, I., Seidel, C. A., Urban, K., Erbersdobler, A., Huland, H., Pantel, K., & Friedrich, M. G. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07600.x · Cited by 38
Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies
Turabi, K. S., Klute, K. A., & Radhakrishnan, P. (2024) · Cancers · doi:10.3390/cancers16132432 · Cited by 48
Parsons, H. A., Beaver, J. A., & Park, B. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_11 · Cited by 41
Liquid biopsy in early stage lung cancer
Pérez-Ramírez, C., Cañadas‐Garre, M., Robles, A. I., Molina‐Vila, M. Á., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.15 · Cited by 41
Galanopoulos, M., Tsoukalas, N., Papanikolaou, I. S., Tolia, M., Gazouli, M., & Mantzaris, G. J. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i4.142 · Cited by 38
Narayan, R. R., Goldman, D. A., Gönen, M., Reichel, J. B., Huberman, K. H., Raj, S. S., Viale, A. J., Kemeny, N. E., Allen, P. J., Balachandran, V. P., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07201-5 · Cited by 38
Nabavizadeh, S. A., Ware, J. B., Guiry, S., Nasrallah, M. P., Mays, J. J., Till, J. E., Hussain, J., Abdalla, A., Yee, S. S., Binder, Z. A., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa016 · Cited by 41
Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers
Hagiwara, N., Mechanic, L. E., Trivers, G. E., Cawley, H., Taga, M., Bowman, E. D., Kumamoto, K., He, P., Bernard, M., Doja, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0991 · Cited by 38
Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Ang, J. E., Kaye, S. B., & Banerji, U. (2012) · Current Drug Targets · doi:10.2174/138945012803530062 · Cited by 39
Spindler, K. G. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1253861 · Cited by 39
Bhangu, J. S., Taghizadeh, H., Braunschmid, T., Bachleitner‐Hofmann, T., & Mannhalter, C. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.08.001 · Cited by 36
Metadata
- Authors
- Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-10-28
- Volume
- 102
- Issue
- 45
- Pages
- 16368-16373
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1283450
- OpenAlex
- W2015438948
- Cited by
- 1,188
- References
- 39
- Citations by year
- 2026: 17 · 2025: 34 · 2024: 44 · 2023: 75 · 2022: 91 · 2021: 76 · 2020: 88 · 2019: 111 · 2018: 97 · 2017: 93 · 2016: 90 · 2015: 66 · 2014: 61 · 2013: 46 · 2012: 44
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA62924, CA43460, CA57345)
- National Cancer Institute (CA 57345, CA43460, R37CA043460, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- circulating tumor DNA, colorectal cancer, APC mutation, liquid biopsy, early cancer detection
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Female, Humans, Male, Middle Aged, Mutation, Sensitivity and Specificity, Colorectal Neoplasms, Genes, APC
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.